Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.66 |
| ▸ | IDO1 | P14902 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.54 |
| ▸ | ADH5 | P11766 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.50 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 1/20 | 0.50 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27360709 | 0.98 | GP6 (0.64) | GP6IDO1ALDH1A1MAPTLMNA | |
| Hydrochloric Acid SCHEMBL7752125 | 0.98 | GP6 (0.64) | GP6IDO1ALDH1A1MAPTLMNA | |
| SCHEMBL5372659 | 0.83 | AURKA (0.58) | GP6IDO1ALDH1A1MAPTLMNA | |
| SCHEMBL25378122 | 0.79 | GP6 (1.00) | GP6IDO1ALDH1A1MAPTADH5 | |
| SCHEMBL12367 | 0.78 | GP6 (0.66) | GP6IDO1ALDH1A1MAPTLMNA | |
| SCHEMBL4258013 | 0.78 | GP6 (0.66) | GP6IDO1ALDH1A1MAPTMETAP2 | |
| SCHEMBL3109571 | 0.78 | GP6 (0.66) | GP6IDO1ALDH1A1MAPTLMNA | |
| SCHEMBL4180199 | 0.78 | GP6 (0.66) | GP6IDO1ALDH1A1MAPTLMNA | |
| SCHEMBL21346024 | 0.78 | GP6 (0.66) | GP6IDO1ALDH1A1MAPTLMNA | |
| SCHEMBL1628598 | 0.78 | GP6 (0.66) | GP6IDO1ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074089-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2013-09-18 | — | — | EP | claimed |
| US-8222248-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-17 | — | — | US | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| US-20250074919-A1 | Heteroaryl compounds as inhibitors of irak4, compositions and applications thereof | ACCRO BIOSCIENCE HK LTD (HK) | 2025-03-06 | — | — | US | disclosed |
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | disclosed |
| EP-4308554-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | The Board of Trustees of the University of Illinois (US) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023130054-A2 | HETEROARYL COMPOUNDS AS INHIBITORS OF IRAK4, COMPOSITIONS AND APPLICATIONS THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2023-07-06 | — | — | WO | disclosed |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-05-11 | — | — | US | disclosed |
| WO-2022197658-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2022-09-22 | — | — | WO | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | NOVO NORDISK A/S (DK) | 2005-03-24 | — | — | US | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| CN-1558762-A | Novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer | ŵ��Ų�ڿ˹�˾ | 2004-12-29 | — | — | CN | disclosed |
| WO-2004080481-A1 | NOVEL NPH INSULIN PREPARATIONS | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004080480-A1 | PHARMACEUTICAL PREPARATIONS COMPRISING ACID-STABILISED INSULIN | NOVO NORDISK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| WO-2004056347-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-07-08 | — | — | WO | disclosed |
| EP-1429763-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2004-06-23 | — | — | EP | disclosed |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | NOVO NORDISK A/S (DK) | 2003-12-11 | — | — | US | disclosed |
| WO-2003027081-A2 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK A/S (DK) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | GP6 2910/4885IDO1 790/4885ALDH1A1 4333/4885 |
| US-20230144211-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | DHFR, FOLR1, MTHFD2 | GP6 917/4885IDO1 1929/4885ALDH1A1 1219/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | GP6 3299/4885IDO1 2867/4885ALDH1A1 3589/4885 |
| US-20030229120-A1 | Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer | IAPP, IRS1, GPR119 | GP6 3513/4885IDO1 3404/4885ALDH1A1 4873/4885 |
| US-20250074919-A1 | Heteroaryl compounds as inhibitors of irak4, compositions and applications thereof | IRAK4, IRAK1, IRAK2 | GP6 2155/4885IDO1 2239/4885ALDH1A1 2304/4885 |
| US-20240199572-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING TYPE 2 DIABETES AND DEMENTIA | SREBF2, SREBF1, SLC2A2 | GP6 4139/4885IDO1 4734/4885ALDH1A1 2469/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | GP6 2889/4885IDO1 633/4885ALDH1A1 4184/4885 |
| US-20050065066-A1 | comprising insulin and novel ligands for the HisB10 Zn2+ sites of the R-state insulin hexamer; physical and chemical stability | IAPP, IRS1, INSR | GP6 2684/4885IDO1 2905/4885ALDH1A1 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.